Bristol Myers Squibb (NYSE:BMY) Upgraded to "Strong-Buy" at Barclays
Barclays has upgraded Bristol Myers Squibb (NYSE:BMY) to a "strong-buy" rating, joining other firms that have recently raised their ratings or price targets for the biopharmaceutical company. Despite a recent earnings per share miss, the company's revenue beat expectations and its positive pipeline, strategic factors, and 2026 guidance support a favorable medium-term outlook. However, recent downward revisions to near-term EPS estimates introduce some caution for short-term upside.
Three Reasons to Keep Buying Enterprise Products Partners
Enterprise Products Partners (EPD) is recommended for buying due to its attractive distribution yield of approximately 6% and 27 consecutive years of increased distributions, reflecting strong cash flow. The company has demonstrated stable historical performance, maintaining consistent cash flow even during economic downturns like the 2007-2009 financial crisis and the COVID-19 pandemic. Furthermore, it boasts strong growth prospects, evidenced by a record $8.7 billion in adjusted cash flow from operations last year, with projected double-digit growth in 2027 driven by new assets and an extensive infrastructure network that positions it to benefit from rising natural gas demand.
Immatics N.V. (IMTX): Investor Outlook Reveals an 85% Upside Potential Amidst Groundbreaking Cancer Therapies
Immatics N.V. (IMTX) is a clinical-stage biopharmaceutical company focused on developing T cell redirecting immunotherapies for solid tumors, presenting a compelling investment case with an 85.68% upside potential despite current financial challenges. The company, with a market capitalization of $1.38 billion, is advancing several therapies through clinical trials and boasts strong strategic collaborations with major healthcare institutions. Analysts maintain a bullish outlook, recommending a 'Buy' with an average target price of $19.13, driven by its pioneering research and partnerships.
Inside Evotec’s Research Engine: What US Partners Need to Know Now
Evotec SE is presented as a strategic R&D partner for US biotech and pharma companies, offering an external research engine from target discovery to IND. The article details Evotec's "Forschung" (research) partnership model, outlining its various collaboration frameworks including fee-for-service, integrated programs, and co-ownership with risk-sharing. It also covers the pros and cons for US partners, highlighting the platform's breadth and scalability against its cost and negotiation complexity.
Inside Evotec’s Research Engine: What US Partners Need to Know Now
Evotec SE is a German drug discovery and development company that has emerged as a significant R&D partner for US biotechs and pharmaceutical firms. This article explores Evotec's "Forschung" (research) partnership model, detailing what it offers—from fee-for-service to risk-sharing agreements—and outlines the pros and cons for US companies. It emphasizes that while Evotec provides deep scientific platforms and flexibility, it is a high-quality, high-cost partner suitable for those prioritizing integration and innovation over budget pricing.
Exelixis: The Cash‑Generating Biotech That I Think Deserves a Closer Look in 2026
Exelixis, a biotech company, has shown strong financial performance over the past five years, largely due to its successful cancer drug, Cabometyx. While Cabometyx faces potential generic competition by early 2030, Exelixis is developing a new cancer medicine, zanzalintinib, and has other pipeline candidates to mitigate this risk. The company's strategic development and strong market position make it a compelling investment consideration.
Deutsche Bank Upgrades Merck (MRK) to Buy, Sees "Clear Path" Beyond Keytruda Patent Cliff
Deutsche Bank has upgraded Merck (MRK) to Buy from Hold, with analyst James Shin increasing the price target to $150 from $115. Shin believes the market is undervaluing Merck due to concerns about Keytruda's patent expiration, but sees a "clear path" for the company beyond this cliff and identifies visible growth drivers outside of Keytruda. This upgrade comes despite Merck's earlier 2026 forecast that fell below Wall Street expectations due to the loss of exclusivity for Januvia and other older medicines.
Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights
Prothena Corporation plc reported its financial results for the fourth quarter and full year 2025, detailing a net loss of $21.6 million and $244.1 million, respectively, and providing a financial guidance for 2026. The company highlighted advancements in its pipeline, including the initiation of Phase 3 clinical trials for prasinezumab and coramitug by its partners Roche and Novo Nordisk, respectively, and the progression of other partnered and proprietary programs. Prothena also discussed its cash position, expected net cash use for 2026, and the potential for a share redemption program.
CHF42.54 close: Bristol-Myers Squibb (BMY.SW, SIX) 20 Feb 2026 oversold bounce
Bristol-Myers Squibb (BMY.SW) closed at CHF 42.54 on February 20, 2026, marking a 4.40% drop and presenting a potential oversold bounce opportunity for short-term traders. The stock exhibits reasonable fundamentals with a PE of 15.99 and a dividend yield of 3.50%, but carries caution due to leverage metrics. Meyka AI rates BMY.SW at 73.32/100, forecasting CHF 39.34 for one year, suggesting limited structural upside but not precluding short-term mean reversion.
Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026?
This article compares Merck (MRK) and Bristol Myers Squibb (BMY) as investment options for 2026, analyzing their fundamentals, growth outlooks, risks, and valuations. While Merck boasts strong oncology sales driven by Keytruda and a robust pipeline, it faces headwinds from patent expirations and declining sales of other drugs. Bristol Myers Squibb also has a strong oncology portfolio and is working to mitigate generic competition for legacy drugs through acquisitions and cost savings. Considering valuation, dividend yield, and near-term outlook, Bristol Myers Squibb is presented as the more compelling investment choice.
Prothena Q4 Earnings Meet Estimates, Pipeline Progress in Focus
Prothena (PRTA) reported a Q4 2025 adjusted loss per share of 45 cents, meeting estimates, but revenues of $0.02 million missed the Zacks Consensus Estimate. Despite a 42% decline in share price over the past year, the company presented a positive outlook for 2026, expecting up to $105 million in clinical milestone payments from collaborations with Bristol Myers Squibb and Novo Nordisk. Prothena's pipeline continues to advance with key programs for Parkinson's disease, ATTR amyloidosis, and Alzheimer's disease progressing through late-stage trials.
Merck vs. Bristol Myers: Which Pharma Stock Is a Better Pick in 2026?
This article compares Merck (MRK) and Bristol Myers Squibb (BMY) as investment opportunities in 2026, analyzing their fundamentals, growth outlooks, risks, and valuations. While Merck boasts strong oncology leadership with Keytruda and a robust pipeline, it faces upcoming patent expirations and declining sales in some segments. Bristol Myers Squibb, despite generic competition for legacy drugs, shows promise with new drug approvals, a strengthened pipeline through strategic acquisitions, and a more favorable valuation and outlook for 2026.
Hepatitis - B Therapeutics Market | Global Market Analysis Report - 2035
The Hepatitis B Therapeutics Market is projected to grow from USD 2.7 billion in 2025 to USD 9.9 billion by 2035, exhibiting a CAGR of 14.1%. This growth is primarily driven by the increasing prevalence of chronic Hepatitis B infections, growing awareness, and advancements in therapeutic research. Anti-viral drugs are expected to dominate the product segment, while hospital pharmacies will lead the distribution channels.
Dr. Reddy’s biosimilar for Bristol’s Orencia gets FDA review
Dr. Reddy's Laboratories has announced that the U.S. Food and Drug Administration (FDA) has accepted for review its marketing application for a biosimilar to Orencia. Orencia, a major arthritis therapy, is currently marketed by Bristol-Myers Squibb. The biosimilar is named DRL_AB.
FDA to review first biosimilar rival to arthritis drug Orencia
Dr. Reddy's Laboratories (RDY) has announced that the U.S. Food and Drug Administration (USFDA) has accepted its 351(k) Biologics License Application (BLA) for DRL_AB, a proposed interchangeable biosimilar to ORENCIA® (abatacept). DRL_AB is intended for the treatment of rheumatoid arthritis, psoriatic arthritis, and polyarticular juvenile idiopathic arthritis. This marks a significant step towards bringing a more cost-effective alternative to market in the United States.
Dr. Reddy’s Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept
Dr. Reddy's Laboratories Ltd. announced that the USFDA has accepted for review its Biologics License Application (BLA) for DRL_AB, a proposed interchangeable biosimilar to ORENCIA® (abatacept). This submission, made in December 2025, represents a significant step towards providing a cost-effective alternative for patients with rheumatoid arthritis, psoriatic arthritis, and polyarticular juvenile idiopathic arthritis. The BLA is supported by comprehensive analytical, pharmacokinetic, and clinical studies demonstrating similarity to the reference product.
BMS and Johnson & Johnson battle over novel CAR-T cell therapy in Europe
BMS and Johnson & Johnson are engaged in a legal battle over their respective CAR-T cell therapies for multiple myeloma in Europe. BMS, through its acquired subsidiary 2seventy bio, has filed a patent infringement lawsuit at the UPC against Johnson & Johnson and Legend Biotech concerning their drug Carvykti. Concurrently, Johnson & Johnson is challenging the patent at the UK High Court and the European Patent Office.
ICICI Prudential Asset Management Co Ltd Grows Stock Holdings in Bristol Myers Squibb Company $BMY
ICICI Prudential Asset Management Co Ltd significantly increased its stake in Bristol Myers Squibb Company (BMY) by 85.8% in Q3, now owning 181,849 shares valued at over $8.2 million. This comes as the FDA accepted BMY’s NDA for an iberdomide combination, granting it priority review with a decision expected by August 2026, offering a potential revenue catalyst. Despite missing Q3 EPS estimates, BMY beat on revenue and raised its quarterly dividend to $0.63, reflecting a 4.2% yield.
Prothena Corporation plc (NASDAQ:PRTA) Q4 2025 Earnings Call Transcript
Prothena Corporation plc discussed their Q4 2025 financial results and provided 2026 guidance, highlighting significant progress in their clinical pipeline with two partner programs, prasinezumab and coramitug, advancing into Phase III trials. The company also introduced its CYTOPE technology for targeting intracellular disease pathways and outlined strategic priorities for 2026, including capturing value from partnerships and potential share redemption. They also discussed progress on BMS-986446 for Alzheimer's and PRX019 for neurodegenerative diseases.
Bristol Myers Squibb Company $BMY Position Trimmed by Jupiter Asset Management Ltd.
Jupiter Asset Management Ltd. has reduced its stake in Bristol Myers Squibb (BMY) by 31.7% in the third quarter, now holding shares worth approximately $41.23 million. This comes as BMY faces mixed sentiment, with the FDA accepting a New Drug Application for an iberdomide combination, potentially creating a new revenue stream, while the company also missed quarterly EPS estimates and received downward revisions from Zacks Research on future earnings. Despite this, BMY increased its quarterly dividend to $0.63, offering a 4.2% yield, and maintains a "Hold" consensus rating from analysts with an average price target of $60.19.
Canaccord Genuity initiates Beam Therapeutics stock with buy rating
Canaccord Genuity has initiated coverage on Beam Therapeutics (NASDAQ:BEAM) with a "buy" rating and a $74.00 price target, citing its late clinical stage, near-term catalysts, and strong execution track record. The firm highlighted Beam's progress with clinical data, successful spin-out acquisitions, and plans for regulatory submissions. Despite Beam's stock underperforming the Nasdaq Biotechnology Index in 2025, it has shown significant momentum in recent months, with analysts largely maintaining a "strong buy" consensus.
King Luther Capital Management Corp Sells 18,602 Shares of Bristol Myers Squibb Company $BMY
King Luther Capital Management Corp reduced its stake in Bristol Myers Squibb by 3.5% in the third quarter, selling 18,602 shares and retaining 517,986 shares valued at approximately $23.36 million. Despite missing EPS estimates at $1.26 (vs. $1.65 consensus), Bristol Myers Squibb's revenue of $12.50 billion surpassed forecasts, and the company raised its quarterly dividend to $0.63, reflecting a 4.2% yield. Institutional ownership remains high at 76.41%, and the stock currently has a "Hold" rating with an average price target of $60.19 among analysts.
Stem Cell and Regenerative Therapy Markets, 2022-2025 & Forecast to 2030 Featuring Profiles of Leading Companies - Gilead Sciences, Novartis, Bristol-Myers Squibb, Organogenesis, MiMedx Group and More
The global stem cell and regenerative therapy market is projected to grow significantly from $16.7 billion in 2025 to $43.8 billion by 2030, driven by technological advancements and increased investments. This growth is fueled by the potential of these therapies to address various chronic health conditions such as cancer, Parkinson's, and diabetes. The market report provides a comprehensive analysis of trends, revenue forecasts, segmentation, and profiles of leading companies like Gilead Sciences, Novartis, and Bristol-Myers Squibb.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Receives Consensus Recommendation of "Buy" from Analysts
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) has received a consensus "Buy" rating from thirteen brokerages, with an average one-year price target of $54.73. Despite insider selling, institutional ownership remains high at 95.45%. The company focuses on developing small-molecule drugs targeting ion channels for neurological and pain disorders.
Texas sues Sanofi, claiming kickbacks to doctors
Texas Attorney General Ken Paxton has filed a lawsuit against Sanofi, alleging the company bribed doctors through a "free nurse" program and "support services" to favor its medicines, including Dupixent, Aubagio, and Tzield. The state claims these services, which bypass administrative hurdles for Medicaid reimbursement, are illegal kickbacks designed to secure revenue rather than prioritize patient needs. Sanofi denies the allegations, stating its programs comply with laws and support patients without influencing prescribing decisions.
BNP PARIBAS ASSET MANAGEMENT Holding S.A. Boosts Stock Position in Biogen Inc. $BIIB
BNP PARIBAS ASSET MANAGEMENT Holding S.A. significantly increased its stake in Biogen Inc. by 20.3% in the third quarter of 2026, now holding 196,903 shares valued at approximately $27.58 million. This comes as Biogen reported strong Q4 earnings, surpassing analyst estimates, and provided FY 2026 guidance. While institutional investment in Biogen remains high, company insider Priya Singhal recently reduced her holdings, and analysts currently hold a mixed "Hold" consensus rating for the stock.
Vanda Awaits FDA Verdict On Atypical Antipsychotic Bysanti
Vanda Pharmaceuticals is awaiting an FDA decision on February 21, 2026, for its atypical antipsychotic drug candidate, Bysanti. Bysanti, an active metabolite of iloperidone, is intended to treat bipolar I disorder and schizophrenia. An approval would grant five years of regulatory data exclusivity and potentially extend patent protection into the 2040s, while also placing it in competition with other established antipsychotics.
Aberdeen Group plc Reduces Stock Holdings in Neurocrine Biosciences, Inc. $NBIX
Aberdeen Group plc significantly reduced its stake in Neurocrine Biosciences (NBIX) by 23.9% in Q3, selling 28,241 shares and ending the quarter with 90,045 shares valued at approximately $12.64 million. This move comes as insiders have also been net sellers, with CEO Kyle Gano reducing his ownership by over 20%. Despite missing Q3 EPS estimates, Neurocrine Biosciences saw a 28.3% year-over-year revenue increase, and analysts collectively rate the stock as a "Moderate Buy" with an average price target of $175.84.
Inside Evotec’s Research Engine: Why US Biotech Partners Are Paying Attention
Evotec SE is presented as a key research partner in drug discovery, offering an integrated R&D platform for biotechs, pharma, and investors. The article details how its "Forschung" offering translates into concrete services for US partners, including target identification, lead optimization, and preclinical development, highlighting its global reach with significant US relevance. It emphasizes Evotec's value proposition of capital efficiency and speed for US founders and R&D executives, positioning it as a strategic infrastructure partner for complex, multi-year discovery strategies.
Tarsus Pharmaceuticals Appoints David Pyott to its Board of Directors
Tarsus Pharmaceuticals has appointed David E. I. Pyott, former chairman and CEO of Allergan, Inc., to its board of directors. Pyott brings extensive global leadership experience in pharmaceuticals, having transformed Allergan into a major specialty pharmaceutical and medical device leader. His appointment is expected to provide invaluable guidance as Tarsus scales its commercial product XDEMVY, advances its pipeline, and aims for sustained growth.
Merck, Mayo Clinic launch AI-driven drug discovery partnership
Merck and Mayo Clinic have formed a partnership to leverage artificial intelligence (AI) and machine learning (ML) with patient data to accelerate drug discovery and development. The collaboration combines Merck's AI research capabilities with Mayo Clinic Platform's infrastructure and extensive clinical datasets, targeting early research decisions in therapeutic areas like gastroenterology, dermatology, and neurology. This move reflects a broader industry trend, with other major pharmaceutical companies also increasing their investments in AI for drug discovery.
Is Bristol Myers Squibb (BMY) Pricing Reflecting DCF And P/E Signals After Recent Share Gains
Bristol Myers Squibb (BMY) appears undervalued according to Discounted Cash Flow (DCF) and Price/Earnings (P/E) analyses, despite recent share gains. The DCF model suggests a 56.7% undervaluation with an intrinsic value of US$137.81 per share, while its P/E ratio of 17.24x is below industry averages and a proprietary "Fair Ratio" of 24.50x. The article presents both bullish and bearish narratives for the stock, offering different fair value estimates based on varying assumptions regarding revenue growth, patent risks, and pipeline execution.
Muscle Invasive Bladder Cancer Market: Pharma Pipeline Fuels Rapid Expansion by 2034 – DelveInsight | CG Oncology, Pfizer, UroGen Pharma, Janssen R&D, Protara Therapeutics, Binhui Biopharmaceutical
The Muscle Invasive Bladder Cancer (MIBC) market is projected for rapid expansion by 2034, driven by an increasing prevalence of the disease, new premium-priced treatment options, and a robust pharmaceutical pipeline. Key market players like CG Oncology, Pfizer, and Janssen R&D are developing advanced therapies, including PD-1 inhibitors and antibody-drug conjugates, that are transforming treatment landscapes, particularly for cisplatin-ineligible patients. Despite challenges like treatment complexity and high costs, significant clinical trial activity and biomarker-driven approaches are expected to fuel future growth.
What Does the Street Have to Say About Bristol-Myers Squibb Company (BMY)?
Bristol-Myers Squibb Company (BMY) has partnered with Life Science Cares to combat food insecurity, investing $30 million and aiming for 30,000 volunteer hours by 2030. Despite a reiterated Hold rating from Bernstein and an Underweight rating from Morgan Stanley, the company reported a 1% growth in fiscal Q4 2025 revenue and significant increases in growth portfolio revenue. BMY's strong financial performance and its role as a biopharmaceutical company in various therapeutic areas are highlighted.
Where is Merck & Co., Inc. (MRK) Headed According to the Street?
Merck & Co., Inc. (MRK) has been upgraded to a Buy rating by Deutsche Bank with a raised price target due to belief that the market undervalues the company despite the looming Keytruda patent cliff. The firm sees a clear path for the company's growth, excluding Keytruda. Additionally, the FDA approved KEYTRUDA® and KEYTRUDA QLEX™ for treating platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal carcinoma with specific PD-L1+ characteristics, marking them as the first and only PD-1 inhibitors for this indication.
Where is Janux Therapeutics (JANX) Headed According to Analysts?
Janux Therapeutics (JANX) is highlighted as a top immunotherapy stock, with JonesTrading maintaining a Buy rating and a $50 price target. The company recently announced a collaboration with Bristol Myers Squibb to develop a novel tumor-activated therapeutic, validating Janux's platform and expanding its oncology reach. Janux will handle preclinical development, while Bristol Myers Squibb will manage subsequent development and commercialization globally.
Bristol Myers Squibb Company $BMY Shares Purchased by Synovus Financial Corp
Synovus Financial Corp increased its stake in Bristol Myers Squibb (NYSE:BMY) by 19.1% in the third quarter, bringing its total holdings to over 311,000 shares valued at $14 million. Other institutional investors, including Vanguard Group Inc. and Charles Schwab Investment Management Inc., also significantly adjusted their positions in the biopharmaceutical company. Analysts have issued a range of ratings, with a consensus "Hold" and an average price target of $59.20, following the company's recent earnings report which missed analyst estimates but showed a 1.3% revenue increase year-over-year.
BioXcel Therapeutics to Host Virtual Roundtable Featuring Leading Medical Experts Addressing Latest Developments in Treatment of Acute Agitation in Alzheimer's Dementia
BioXcel Therapeutics is hosting a virtual roundtable on February 27, 2026, to discuss acute agitation in Alzheimer's dementia, an area with significant unmet medical need and no FDA-approved treatments. The event will highlight the potential of their investigational product BXCL501, which is currently being evaluated in the TRANQUILITY In-Care Phase 3 trial. Leading medical experts will participate to shed light on this condition that affects approximately 100 million annual episodes.
Pzena Investment Management LLC Acquires 58,129 Shares of Bristol Myers Squibb Company $BMY
Pzena Investment Management LLC increased its stake in Bristol Myers Squibb Company by 0.4% in the third quarter, bringing its total holdings to over 14.9 million shares valued at approximately $672.1 million. This increase makes Bristol Myers Squibb the 18th largest position in Pzena's portfolio. The biopharmaceutical company recently reported missing quarterly EPS estimates but affirmed its FY2026 guidance, raised its quarterly dividend, and holds a consensus "Hold" rating from analysts.
Cytokinetics Secures Triple Crown: EU Approval of MYQORZO Solidifies Global Reach in Cardiovascular Market
Cytokinetics has received marketing authorization from the European Commission for its heart failure drug, MYQORZO (aficamten), completing a global regulatory "triple crown" after prior approvals in the US and China. This approval expands the company's cardiovascular franchise into the European market, positioning it as a significant player in treating obstructive hypertrophic cardiomyopathy (oHCM). The move shifts Cytokinetics to a commercial execution story, challenging competitors like Bristol Myers Squibb, and its shares have already seen a substantial surge based on anticipated regulatory victories.
Skandinaviska Enskilda Banken AB publ Reduces Holdings in Neurocrine Biosciences, Inc. $NBIX
Skandinaviska Enskilda Banken AB publ has reduced its stake in Neurocrine Biosciences, Inc. by 15.6% in the third quarter, now holding 61,118 shares worth approximately $8.58 million. This comes as insider selling by CEO Kyle Gano and Director Leslie V. Norwalk has also accelerated, with Gano selling 20.6% of his holding and insiders collectively selling 61,966 shares recently. Despite institutional investors owning 92.59% of the stock, Neurocrine Biosciences reported Q3 EPS of $1.88, missing estimates, while revenue increased by 28.3% year-over-year.
Neuropsychiatry Market Is Going to Boom | Pfizer Inc. • Bristol-Myers Squibb • AstraZeneca
Coherent Market Insights has published a new report detailing the "Neuropsychiatry Market: Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2026-2033." The report offers an in-depth analysis of market competition, geographic distribution, growth potential, and key success factors, targeting entrepreneurs, investors, and business strategists. It identifies major market players as well as segmentations and includes a comprehensive regional analysis.
Morgan Stanley Keeps Their Buy Rating on BioNTech SE (BNTX)
Morgan Stanley analyst Terence Flynn maintained a Buy rating for BioNTech SE (BNTX) with a price target of $134.00, citing a 60.76% success rate and 12.0% average return. Despite corporate insider sentiment being negative due to increased selling, the overall analyst consensus for BioNTech SE is a Strong Buy with an average price target of $143.80. BioNTech SE reported a quarterly revenue of $1.52 billion and GAAP net loss of $28.7 million in its latest earnings release.
Health care’s next chapter: Opportunities in an era of transformation
The health care sector is entering a new era of innovation, presenting compelling opportunities for investors despite past challenges. Key subsectors like biotech, life science tools, and managed care are driving this transformation, fueled by scientific advancements and evolving market dynamics. Active management and rigorous research are deemed essential for navigating the sector's complexities and identifying leading companies.
Novartis/Unnatural Team Up On Macrocyclic Peptides
Novartis has partnered with Unnatural Products to collaborate on the development of macrocyclic peptides. This collaboration aims to leverage the expertise of both companies in drug discovery. The article was published on February 18, 2026.
Glaukos Stock Shoots Up After iDose TR Re-administration Approval
Glaukos Corporation (NYSE: GKOS) stock surged over 13% following FDA approval for the re-administration of its iDose TR glaucoma therapy, indicating enhanced patient safety and effectiveness. This regulatory validation has led to increased investor confidence, with Stifel raising Glaukos's price target to $160, and the company forecasting 2026 revenue to exceed expectations due to strategic market positioning and innovative solutions. Recent Q4 revenues also outperformed analyst predictions, underscoring the success of its eyecare products and promising financial health moving forward.
FDA Accepts BMY's NDA for Iberdomide Combo in Multiple Myeloma
Bristol Myers Squibb (BMY) announced that the FDA has accepted its new drug application (NDA) for iberdomide in combination with standard therapies for relapsed or refractory multiple myeloma (RRMM). The FDA granted priority review, with a decision expected by August 17, 2026, and also gave iberdomide Breakthrough Therapy designation for this indication. This proprietary drug, a novel CELMoD, aims to establish a new treatment foundation for multiple myeloma.
FDA Accepts BMY's NDA for Iberdomide Combo in Multiple Myeloma
Bristol Myers Squibb (BMY) announced that the FDA has accepted its new drug application (NDA) for iberdomide, in combination with standard therapies, to treat relapsed or refractory multiple myeloma. The FDA granted priority review status, with a decision expected by August 17, 2026, and also gave iberdomide Breakthrough Therapy designation for this indication. This NDA is based on positive data from the phase III EXCALIBER-RRMM study, and iberdomide represents a novel class of medicines aimed at creating a new foundation for multiple myeloma treatment.
Pfizer Targets Real-World Myeloma Data in Taiwan With New Elranatamab Study
Pfizer Inc. is initiating a new real-world observational study in Taiwan to evaluate the effectiveness of its multiple myeloma drug, elranatamab, in a routine hospital environment. This study aims to collect data on actual patient outcomes and treatment patterns, supporting the drug's longer-term acceptance and market share in Asia. While the study is not yet recruiting, its progress indicates Pfizer's commitment to its oncology portfolio, with potential positive impacts on pricing and reimbursement discussions in the future.
Evinova Announces Strategic Collaborations with Astellas, AstraZeneca and Bristol Myers Squibb Advancing Its AI-Native Platform to Accelerate Global Clinical Development
Evinova has announced strategic collaborations with Astellas Pharma Inc., AstraZeneca, and Bristol Myers Squibb to accelerate global clinical development using its AI-native platform. These partnerships involve sharing operational data to enhance the platform's recommendations, aiming for faster trials and improved patient outcomes. The AI-driven platform offers solutions like Study Designer, AI Authoring, and AI Digitizer to optimize study design, streamline document creation, and convert clinical data into machine-readable formats, significantly reducing costs and timelines for drug development.
